Your browser doesn't support javascript.
loading
PIAS family in cancer: from basic mechanisms to clinical applications.
Li, Xiaomeng; Rasul, Azhar; Sharif, Farzana; Hassan, Mudassir.
Afiliación
  • Li X; KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Rasul A; Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan.
  • Sharif F; Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan.
  • Hassan M; Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan.
Front Oncol ; 14: 1376633, 2024.
Article en En | MEDLINE | ID: mdl-38590645
ABSTRACT
Protein inhibitors of activated STATs (PIAS) are proteins for cytokine signaling that activate activator-mediated gene transcription. These proteins, as versatile cellular regulators, have been described as regulators of approximately 60 proteins. Dysregulation of PIAS is associated with inappropriate gene expression that promotes oncogenic signaling in multiple cancers. Multiple lines of evidence have revealed that PIAS family members show modulated expressions in cancer cells. Most frequently reported PIAS family members in cancer development are PIAS1 and PIAS3. SUMOylation as post-translational modifier regulates several cellular machineries. PIAS proteins as SUMO E3 ligase factor promotes SUMOylation of transcription factors tangled cancer cells for survival, proliferation, and differentiation. Attenuated PIAS-mediated SUMOylation mechanism is involved in tumorigenesis. This review article provides the PIAS/SUMO role in the modulation of transcriptional factor control, provides brief update on their antagonistic function in different cancer types with particular focus on PIAS proteins as a bonafide therapeutic target to inhibit STAT pathway in cancers, and summarizes natural activators that may have the ability to cure cancer.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza